| Abstract: | The results of a clinical trial in patients with generalized Burkitt's lymphoma using either multiple doses of cyclophosphamide or a cyclic, sequential regimen employing cylophosphamide, vincristine, methotrexate, and cytosine arabinoside (TRIKE) are reported. Of 42 evaluable patients 24 received cyclophosphamide and 18 received TRIKE. No significant differences were encountered between either group with respect to remission induction, relapse rate or survival. Remission duration was significantly prolonged in the patients receiving cyclophosphamide, but this event has little effect on survival. Although intensive chemotherapy is probably necessary in patients with generalized Burkitt's lymphoma, other variables such as meningeal involvement and immunologic factors appear to affect relapse and survival. |
